IMI (International Medical Innovations) begins trial of early cancer markers
This article was originally published in Clinica
Executive Summary
Canadian company International Medical Innovations (IMI) has begun trials of two new screening tests for early diagnosis of colorectal cancer, the third most common cancer in North America. It is the first large trial of the tests, known as CA1-18 and RMT, says Dr Norman Marcon, a gastroenterologist at St Michael's Hospital Toronto, where the 600-patient study is being carried out.
You may also be interested in...
California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits
The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.